Nonalcoholic fatty liver disease, diet and gut microbiota

EXCLI Journal

Volumn 13, Issue , 2014, Pages 461-490

  Finelli, Carmine ^a   Tarantino, Giovanni ^b,c  

^a Stella Maris Mediterraneum Foundation   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Gut microbiome; Interventions; NAFLD

Indexed keywords

ALCOHOL; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREBIOTIC AGENT; PROBIOTIC AGENT; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1;

AMINO ACID METABOLISM; ANTIINFLAMMATORY ACTIVITY; BACTERIAL OVERGROWTH; BODY COMPOSITION; DIET; DIET SUPPLEMENTATION; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; GENE MUTATION; HUMAN; INCIDENCE; INNATE IMMUNITY; INSULIN RESISTANCE; INTERVENTION STUDY; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIFESTYLE MODIFICATION; LIVER; LIVER TOXICITY; METABOLIC REGULATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; REVIEW;

EID: 84900421213     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Review

References (211)

1. Abedi D, Feizizadeh S, Akbari V, Jafarian-Dehkordi A. In vitro anti-bacterial and anti-adherence effects of Lactobacillus delbrueckii subsp bulgaricus on Escherichia coli. Res Pharm Sci 2013;8:260-268.
2. Abhilash PA, Harikrishnan R, Indira M. Ascorbic acid suppresses endotoxemia and NF-κB signaling cascade in alcoholic liver fibrosis in guinea pigs: A mechanistic approach. Toxicol Appl Pharmacol 2014;274:215-224.
3. Ahmed M, El-Bakly WM, Zaki AM, Abd Alzez LF, El Serafi O. Bupropion effects on high-fat diet-induced steatohepatitis and endothelial dysfunction in rats: role of tumour necrosis factor-alpha. J Pharm Pharmacol 2014. doi: 10.1111/jphp.12213. [Epub ahead of print].
4. Ahrne S, Hagslatt ML. Effect of lactobacilli on pa-racellular permeability in the gut. Nutrients 2011;3: 104-117.
5. Ait-Belgnaoui A, Colom A, Braniste V, Ramalho L, Marrot A, Cartier C et al. Probiotic gut effect prevents the chronic psychological stress-induced brain activity abnormality in mice. Neurogastroenterol Motil 2013. doi: 10.1111/nmo.12295. [Epub ahead of print]
6. Ancel D, Barraud H, Peyrin-Biroulet L, Bronowicki JP. Intestinal permeability and cirrhosis. Gastroen-terol Clin Biol 2006;30:460-468.
7. Alkhouri N, Berk M, Yerian L, Lopez R, Chung YM, Zhang R et al. OxNASH Score Correlates with Histologic Features and Severity of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2014 [Epub ahead of print].
8. Alkhouri N, Cikach F, Eng K, Moses J, Patel N, Yan C et al. Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children. Eur J Gastroen-terol Hepatol 2014b;26:82-87.
9. Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr 2014;54:938-956.
10. Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, Karatza E, Triantos C, Vagianos CE et al. Altered intestinal tight junctions' expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest 2012;42: 439-446.
11. Atkinson MA, Chervonsky A. Does the gut microbi-ota have a role in type 1 diabetes? Early evidence from humans and animal models of the disease. Dia-betologia 2012;55:2868-2877.
12. Audy J, Mathieu O, Belvis J, Tompkins TA. Trans-criptomic response of immune signalling pathways in intestinal epithelial cells exposed to lipopoly-saccharides, Gram-negative bacteria or potentially probiotic microbes. Benef Microbes 2012;3:273-286.
13. Bain MA, Fornasini G, Evans AM. Trimethylamine: metabolic, pharmacokinetic and safety aspects. Curr Drug Metab 2005;6:227-240.
14. Banjoko IO, Adeyanju MM, Ademuyiwa O, Ade-bawo OO, Olalere RA, Kolawole MO et al. Hypoli-pidemic effects of lactic acid bacteria fermented cereal in rats. Lipids Health Dis 2012;11:170.
15. Bedani R, Rossi EA, Isay Saad SM. Impact of inulin and okara on Lactobacillus acidophilus La-5 and Bifidobacterium animalis Bb-12 viability in a fermented soy product and probiotic survival under in vitro simulated gastrointestinal conditions. Food Mi-crobiol 2013;34:382-389.
16. Bellot P, Francés R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013;33:31-39.
17. Belforte FS, Coluccio Leskow F, Poskus E, Penas Steinhardt A. Toll-like receptor 4 D299G polymorphism in metabolic disorders: a meta-analysis. Mol Biol Rep 2013;40:3015-3020.
18. Benjamin J, Singla V, Arora I, Sood S, Joshi YK. Intestinal permeability and complications in liver cirrhosis: A prospective cohort study. Hepatol Res 2013;43:200-207.
19. Bertazzoni E, Donelli G, Midtvedt T, Nicoli J, Sanz Y. Probiotics and clinical effects: is the number what counts? J Chemother 2013;25:193-212.
20. Blaut M, Klaus S. Intestinal microbiota and obesity. Handb Exp Pharmacol 2012;(209): 251-273. doi: 10.1007/978-3-642-24716-3_11
21. Bouin M, Vincent C, Bouhier K, Debruyne D, Fatome A, Piquet MA et al. Increased oro-cecal transit time in grade I or II hepatic encephalopathy. Gastroenterol Clin Biol 2004;28:1240-1244.
22. Bomhof MR, Saha DC, Reid DT, Paul HA, Reimer RA. Combined effects of oligofructose and Bifido-bacterium animalis on gut microbiota and glycemia in obese rats. Obesity (Silver Spring) 2014;22:763-771.
23. Buccigrossi V, Nicastro E, Guarino A. Functions of intestinal microflora in children. Curr Opin Gastro-enterol 2013;29:31-38.
24. Bull-Otterson L, Feng W, Kirpich I, Wang Y, Qin X, Liu Y et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal micro-biome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One 2013;8:e53028.
25. Bures J, Cyrany J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010;16: 2978-2990.
26. Cariello R, Federico A, Sapone A, Tuccillo C, Scialdone VR, Tiso A et al. Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage. Dig Liver Dis 2010;42:200-204.
27. Carstensen M, Wiza C, Röhrig K, Fahlbusch P, Ro-den M, Herder C et al. Effect of sfrp5 on cytokine release and insulin action in primary human adipo-cytes and skeletal muscle cells. PLoS One 2014;9: e85906.
28. Carvalho BM, Saad MJ. Influence of gut microbiota on subclinical inflammation and insulin resistance. Mediators Inflamm. 2013; 2013: 986734.
29. Charlton M. Evolving aspects of liver transplantation for non-alcoholic steatohepatitis. Curr Opin Organ Transplant 2013;18:251-258.
30. Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Ga-strointest Liver Physiol 2011;300:G697-G702.
31. Chen TF, Yadav PK, Wu RJ, Yu WH, Liu CQ, Lin H et al. Comparative evaluation of intragastric bile acids and hepatobiliary scintigraphy in the diagnosis of duodenogastric reflux. World J Gastroenterol 2013;19:2187-2196.
32. Cherrington NJ, Estrada TE, Frisk HA, Canet MJ, Hardwick RN, Dvorak B et al. The hepatic bile acid transporters Ntcp and Mrp2 are downregulated in experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 2013;304:G48-G56.
33. Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, Li K et al. Antibiotics in early life alter the murine co-lonic microbiome and adiposity. Nature 2012;488: 621-626.
34. Cho KO, Jo YJ, Song BK, Oh JW, Kim YS. Colon transit time according to physical activity and characteristics in South Korean adults. World J Gastro-enterol 2013;19:550-555.
35. Cirin DM, Poša MM, Krstonošić VS. Interactions between selected bile salts and Triton X-100 or sodium lauryl ether sulfate. Chem Cent J 2011;5:89.
36. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40 (suppl 1):S5-10.
37. Closa-Monasterolo R, Gispert-Llaurado M, Luque V, Ferre N, Rubio-Torrents C, Zaragoza-Jordana M et al. Safety and efficacy of inulin and oligofructose supplementation in infant formula: results from a randomized clinical trial. Clin Nutr 2013;32:918-927.
38. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol 2012; 28:159-165.
39. Craciun S, Balskus EP. Microbial conversion of cho-line to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci U S A 2012;109:21307-21312.
40. Delzenne NM, Cani PD, Neyrinck AM. Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose: experimental data. J Nutr 2007;137:2547S-2551S.
41. Demignot S, Beilstein F, Morel E. Triglyceride-rich lipoproteins and cytosolic lipid droplets in ente-rocytes: key players in intestinal physiology and metabolic disorders. Biochimie 2014;96:48-55.
42. Dewulf EM, Cani PD, Neyrinck AM, Possemiers S, Van Holle A, Muccioli GG et al. Inulin-type fruc-tans with prebiotic properties counteract GPR43 overexpression and PPARγ-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. J Nutr Biochem 2011;22:712-722.
43. Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013;62:1112-1121.
44. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008;83:460-469.
45. Di Renzo L, Sarlo F, Petramala L, Iacopino L, Mon-teleone G, Colica C et al. Association between -308 G/A TNF-α polymorphism and appendicular skeletal muscle mass index as a marker of sarcopenia in normal weight obese syndrome. Dis Markers 2013; 35:615-623.
46. Druart C, Neyrinck AM, Vlaeminck B, Fievez V, Cani PD, Delzenne NM. Role of the Lower and Upper Intestine in the Production and Absorption of Gut Microbiota-Derived PUFA Metabolites. PLoS One 2014;9:e87560.
47. Duseja A, Chawla YK. Obesity and NAFLD: The role of bacteria and microbiota. Clin Liver Dis 2014; 18:59-71.
48. Eizaguirre I, Aldazabal P, Urkia NG, Asensio A, Arenzxana JM. Escherichia coli translocation in experimental short bowel syndrome: probiotic supplementation and detection by polymerase chain reaction. Pediatr Surg Int 2011;27:1301-1305.
49. Estrela S, Brown SP. Metabolic and demographic feedbacks shape the emergent spatial structure and function of microbial communities. PLoS Comput Biol 2013;9:e1003398.
50. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB et al. Cross-talk between Ak-kermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 2013;110:9066-9071.
51. Fava F, Gitau R, Griffin BA, Gibson GR, Tuohy KM, Lovegrove JA. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population. Int J Obes (Lond) 2013; 37:216-223.
52. Finelli C, Tarantino G. Is visceral fat reduction necessary to favour metabolic changes in the liver? J Gastrointestin Liver Dis 2012a;21:205-208.
53. Finelli C, Tarantino G. Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients? J Gastrointest Liver Dis 2012b; 21:293-302.
54. Finelli C, Tarantino G. What is the role of adiponec-tin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol 2013a;19:802-812.
55. Finelli C, Tarantino G. Obesity paradox or meta-bolically benign obesity? Eat Weight Disord 2013b; 18:337-338.
56. Finelli C, Tarantino G. Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival? Hepatol Int 2013c;7:413-428.
57. Fleissner CK, Huebel N, Abd El-Bary MM, Loh G, Klaus S, Blaut M. Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br J Nutr 2010;104:919-929.
58. Flint HJ. Obesity and the gut microbiota. J Clin Gas-troenterol 2011;45(Suppl):S128-S132.
59. Fouhy F, O'Connell Motherway M, Fitzgerald GF, Ross RP, Stanton C, Cotter PD. In silico assigned resistance genes confer bifidobacterium with partial resistance to aminoglycosides but not to β-lactams. PLoS One 2013;8:e82653.
60. Fukunishi S, Sujishi T, Takeshita A, Ohama H, Tsu-chimoto Y, Asai A et al. Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats. J Clin Bio-chem Nutr 2014;54:39-44.
61. Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. Prevention and treatment of hepatic encephalopathy:focusing on gut microbiota. World J Gastroenterol 2012;18:6693-6700.
62. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB. Dietary modulation of the human colonic microbiota:updating the concept of prebiot-ics. Nutr Res Rev 2004;17:259-275.
63. Gigante G, Tortora A, Ianiro G, Ojetti V, Purchiaro-ni F, Campanale M et al. Role of gut microbiota in food tolerance and allergies. Dig Dis 2011;29:540-549.
64. Gonciarz M, Bielański W, Partyka R, Brzozowski T, Konturek PC, Eszyk J et al. Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with mela-tonin. J Pineal Res 2013;54:154-161.
65. Gonzalez-Quintela A, Alonso M, Campos J, Vizcaino L, Loidi L, Gude F. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population:the role of obesity. PLoS One 2013;8:e54600.
66. Greene MW, Burrington CM, Lynch DT, Davenport SK, Johnson AK, Horsman MJ et al. Lipid metabolism, oxidative stress and cell death are regulated by PKC delta in a dietary model of nonalcoholic steato-hepatitis. PLoS One 2014;9:e85848.
67. Gunnarsdottir SA, Sadik R, Shev S, Simrén M, Sjövall H, Stotzer PO et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol 2003;98:1362-1370.
68. Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encepha-lopathy. J Hepatol 2010;53:849-855.
69. Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A et al. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr 2012;95:892-900.
70. Hada M, Omura K, Hirano Y, Watanabe G. Changes in bowel mucosal permeability and wound healing after neoadjuvant chemotherapy. Oncol Lett 2010; 1:161-5.
71. Hagey LR, Krasowski MD. Microbial biotransfor-mations of bile acids as detected by electrospray mass spectrometry. Adv Nutr 2013;4:29-35.
72. Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fu-kui M, Kato T. Protective effect of alcohol consumption for fatty liver but not metabolic syndrome. World J Gastroenterol 2012;18:156-167.
73. Hartley L, Flowers N, Holmes J, Clarke A, Stranges S, Hooper L et al. Green and black tea for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;6:CD009934.
74. Harvey SA, Dangi A, Tandon A, Gandhi CR. The transcriptomic response of rat hepatic stellate cells to endotoxin:implications for hepatic inflammation and immune regulation. PLoS One 2013;8:e82159.
75. Hawkesworth S, Moore SE, Fulford AJ, Barclay GR, Darboe AA, Mark H et al. Evidence for metabolic endotoxemia in obese and diabetic Gambian women. Nutr Diabetes 2013;3:e83.
76. Henao-Mejia J, Elinav E, Thaiss CA, Flavell RA. The intestinal microbiota in chronic liver disease. Adv Immunol 2013;117:73-97.
77. Henning SM, Wang P, Abgaryan N, Vicinanza R, de Oliveira DM, Zhang Y et al. Phenolic acid concentrations in plasma and urine from men consuming green or black tea and potential chemopreventive properties for colon cancer. Mol Nutr Food Res 2013;57:483-493.
78. Hodin CM, Visschers RG, Rensen SS, Boonen B, Olde Damink SW, Lenaerts K et al. Total parenteral nutrition induces a shift in the firmicutes to bac-teroidetes ratio in association with paneth cell activation in rats. J Nutr 2012;142:2141-2147.
79. Hsieh FC, Lee CL, Chai CY, Chen WT, Lu YC, Wu CS. Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. Nutr Metab (Lond) 2013;10:35.
80. Huang WC, Hung MC. Beyond NF-κB activation: nuclear functions of IκB kinase α. J Biomed Sci 2013;20:3.
81. Ilan Y. Leaky gut and the liver:a role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol 2012;18:2609-2618.
82. Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic stea-tohepatitis is regulated by leptin-mediated signaling. Cell Metab 2012;16:44-54.
83. Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Se-min Immunopathol 2014;36:115-132.
84. Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SS. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther 2013;37:1103-1111.
85. Jones ML, Tomaro-Duchesneau C, Martoni CJ, Pra-kash S. Cholesterol lowering with bile salt hydrola-se-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. Expert Opin Biol Ther 2013;13: 631-642.
86. Kallus SJ, Brandt LJ. The intestinal microbiota and obesity. J Clin Gastroenterol 2012;46:16-24.
87. Karatepe O, Acet E, Battal M, Adas G, Kemik A, Altiok M et al. Effects of glutamine and curcumin on bacterial translocation in jaundiced rats. World J Gastroenterol 2010;16:4313-4320.
88. Karlsson F, Tremaroli V, Nielsen J, Bäckhed F. Assessing the human gut microbiota in metabolic diseases. Diabetes 2013;62:3341-3349.
89. Kawaratani H, Tsujimoto T, Douhara A, Takaya H, Moriya K, Namisaki T et al. The effect of inflammatory cytokines in alcoholic liver disease. Mediators Inflamm 2013;2013:495156.
90. Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver dis-ease;a systematic review on the current evidences. Hepat Mon 2013;13:e7233.
91. Kim JH. The physical activity level in female affects colon transit time. J Neurogastroenterol Motil 2012; 18:4-5.
92. Kirsch R, Clarkson V, Verdonk RC, Marais AD, Shephard EG, Ryffel B et al. Rodent nutritional model of steatohepatitis:effects of endotoxin (lipopoly-saccharide) and tumor necrosis factor alpha deficiency. J Gastroenterol Hepatol 2006;21:174-182.
93. Kiziltas S, Ata P, Colak Y, Mesçi B, Senates E, Enc F et al. TLR4 gene polymorphism in patients with nonalcoholic fatty liver disease in comparison to healthy controls. Metab Syndr Relat Disord 2014;12: 165-170.
94. Koleva PT, Valcheva RS, Sun X, Gänzle MG, Die-leman LA. Inulin and fructo-oligosaccharides have divergent effects on colitis and commensal micro-biota in HLA-B27 transgenic rats. Br J Nutr 2012; 108:1633-1643.
95. Krautbauer S, Eisinger K, Neumeier M, Hader Y, Buettner R, Schmid PM et al. Free fatty acids, lipo-polysaccharide and IL-1a induce adipocyte manganese superoxide dismutase which is increased in visceral adipose tissues of obese rodents. PLoS One 2014;9:e86866.
96. Krznarić Z, Vranešić Bender D, Kunović A, Kekez D, Stimac D. Gut microbiota and obesity. Dig Dis 2012;30:196-200.
97. Lamontagne A, Long RE, Comunale MA, Hafner J, Rodemich-Betesh L, Wang M et al. Altered functionality of anti-bacterial antibodies in patients with chronic hepatitis C virus infection. PLoS One 2013; 8:e64992.
98. Lee CY. The effect of high-fat diet-induced pathophysiological changes in the gut on obesity: what should be the ideal treatment? Clin Transl Gastroenterol 2013;4:e39.
99. Létoffé S, Audrain B, Bernier SP, Delepierre M, Ghigo JM. Aerial exposure to the bacterial volatile compound trimethylamine modifies antibiotic resistance of physically separated bacteria by raising culture medium pH. MBio 2014;5:e00944-e00913.
100. Li HP, Chen X, Li MQ. Butyrate alleviates metabolic impairments and protects pancreatic (3 cell function in pregnant mice with obesity. Int J Clin Exp Pathol 2013;6:1574-1584.
101. Li W, Yang S, Kim SO, Reid G, Challis JR, Bocking AD. Lipopolysaccharide-induced profiles of cytokine, chemokine, and growth factors produced by human decidual cells are altered by Lactobacillus rhamnosus GR-1 Supernatant. Reprod Sci 2014 [Epub ahead of print].
102. Ling GS, Bennett J, Woollard KJ, Szajna M, Fossa-ti-Jimack L, Taylor PR et al. Integrin CD11b positively regulates TLR4-induced signalling pathways in dendritic cells but not in macrophages. Nat Commun 2014;5:3039.
103. Lorenzo M, Fernández-Veledo S, Vila-Bedmar R, Garcia-Guerra L, De Alvaro C, Nieto-Vazquez I. Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes. J Anim Sci 2008;86(14 Suppl):E94-E104.
104. Lunia MK, Sharma BC, Sharma P, Sachdeva S, Sri-vastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis:a randomized controlled trial. Clin Gastroenterol Hepatol 2013 [Epub ahead of print].
105. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver dis-ease:a meta-analysis. World J Gastroenterol 2013; 19:6911-6918.
106. Macfarlane GT, Macfarlane S. Bacteria, colonic fermentation, and gastrointestinal health. J AOAC Int 2012;95:50-60.
107. Machado MV, Coutinho J, Carepa F, Costa A, Proença H, Cortez-Pinto H. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2012;24:1166-1172.
108. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49: 1877-1887.
109. Miyauchi E, Ogita T, Miyamoto J, Kawamoto S, Morita H, Ohno H et al. Bifidobacterium longum alleviates dextran sulfate sodium-induced colitis by suppressing IL-17A response:involvement of intestinal epithelial costimulatory molecules. PLoS One 2013;8:e79735.
110. Moran-Ramos S, Tovar AR, Torres N. Diet: friend or foe of enteroendocrine cells - how it interacts with enteroendocrine cells. Adv Nutr 2012;3:8-20.
111. Murphy EF, Cotter PD, Healy S, Marques TM, O'Sullivan O, Fouhy F et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 2010;59:1635-1642.
112. Murri M, Leiva I, Gomez-Zumaquero JM, Tinaho-nes FJ, Cardona F, Soriguer F et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children:a case-control study. BMC Med 2013;11:46.
113. Mushref MA, Srinivasan S. Effect of high fat-diet and obesity on gastrointestinal motility. Ann Transl Med 2013;1:14.
114. Nair S, Cope K, Risby TH, Diehl AM. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:1200-1204. Erratum in: Am J Gastroenterol 2001;96:2809.
115. Noda S, Tanabe S, Suzuki T. Naringenin enhances intestinal barrier function through the expression and cytoskeletal association of tight junction proteins in Caco-2 cells. Mol Nutr Food Res 2013;57:2019-2028.
116. O'Connell Motherway M, Kinsella M, Fitzgerald GF, van Sinderen D. Transcriptional and functional characterization of genetic elements involved in galacto-oligosaccharide utilization by Bifidobacte-rium breve UCC2003. Microb Biotechnol 2013;6: 67-79.
117. Osman N, Adawi D, Ahrné S, Jeppsson B, Molin G. Endotoxin- and D-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry. Dig Liver Dis 2007; 39:849-856.
118. Osto M, Abegg K, Bueter M, le Roux CW, Cani PD, Lutz TA. Roux-en-Y gastric bypass surgery in rats alters gut microbiota profile along the intestine. Physiol Behav 2013;119:92-96.
119. Pande C, Kumar A, Sarin SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther 2009; 29:1273-1281.
120. Parnell JA, Reimer RA. Weight loss during oligo-fructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 2009;89: 1751-1759.
121. Penas-Steinhardt A, Barcos LS, Belforte FS, de Se-reday M, Vilariño J, Gonzalez CD et al. Functional characterization of TLR4 +3725 G/C polymorphism and association with protection against overweight. PLoS One 2012;7:e50992.
122. Pedersen C, Lefevre S, Peters V, Patterson M, Ghatei MA, Morgan LM et al. Gut hormone release and appetite regulation in healthy non-obese participants following oligofructose intake. A dose-escalation study. Appetite 2013;66:44-53.
123. Penno MA, Couper JJ, Craig ME, Colman PG, Rawlinson WD, Cotterill AM et al. Environmental determinants of islet autoimmunity (ENDIA):a pregnancy to early life cohort study in children at-risk of type 1 diabetes. BMC Pediatr 2013;13:124.
124. Pinzone MR, Celesia BM, Di Rosa M, Cacopardo B, Nunnari G. Microbial translocation in chronic liver diseases. Int J Microbiol 2012;2012:694629.
125. Plaudis H, Pupelis G, Zeiza K, Boka V. Early low volume oral synbiotic/prebiotic supplemented ente-ral stimulation of the gut in patients with severe acute pancreatitis:a prospective feasibility study. Acta Chir Belg 2012;112:131-138.
126. Pourghassem Gargari B, Dehghan P, Aliasgharzadeh A, Asghari Jafar-Abadi M. Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes. Diabetes Metab J 2013;37:140-148.
127. Pyra KA, Saha DC, Reimer RA. Prebiotic fiber increases hepatic acetyl CoA carboxylase phosphory-lation and suppresses glucose-dependent insulino-tropic polypeptide secretion more effectively when used with metformin in obese rats. J Nutr 2012;142: 213-220.
128. Queipo-Ortuño MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F et al. Gut micro-biota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels. PLoS One 2013;8:e65465.
129. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464(7285):59-65.
130. Racioppi L, Noeldner PK, Lin F, Arvai S, Means AR. Calcium/calmodulin-dependent protein kinase kinase 2 regulates macrophage-mediated inflammatory responses. J Biol Chem 2012;287:11579-11591.
131. Rana SV, Bhardwaj SB. Small intestinal bacterial overgrowth. Scand J Gastroenterol 2008;43:1030-1037.
132. Rana SV, Sharma S, Kaur J, Prasad KK, Sinha SK, Kochhar R et al. Relationship of cytokines, oxidative stress and GI motility with bacterial overgrowth in ulcerative colitis patients. J Crohns Colitis 2014 [Epub ahead of print].
133. Rai AK, Debetto P, Sala FD. Molecular regulation of cholesterol metabolism:HDL-based intervention through drugs and diet. Indian J Exp Biol 2013;51: 885-894.
134. Rao RK, Samak G. Protection and restitution of gut barrier by probiotics:nutritional and clinical implications. Curr Nutr Food Sci 2013;9:99-107.
135. Rauch M, Lynch SV. The potential for probiotic manipulation of the gastrointestinal microbiome. Curr Opin Biotechnol 2012;23:192-201.
136. Reimer RA, Grover GJ, Koetzner L, Gahler RJ, Juneja P, Lyon MR et al. Sitagliptin reduces hyper-glycemia and increases satiety hormone secretion more effectively when used with a novel polysac-charide in obese Zucker rats. J Nutr 2012; 142:1812-1820.
137. Remely M, Aumueller E, Merold C, Dworzak S, Hippe B, Zanner J et al. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene 2014; 537:85-92.
138. Rezzi S, Ramadan Z, Fay LB, Kochhar S. Nutritional metabonomics:applications and perspectives. J Proteome Res 2007;6:513-525.
139. Ritze Y, Bárdos G, Claus A, Ehrmann V, Bergheim I, Schwiertz A et al. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS One 2014;9:e80169.
140. Rodríguez-Hernández H, Simental-Mendía LE, Rodríguez-Ramírez G, Reyes-Romero MA. Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol 2013; 2013:678159.
141. Roh YS, Seki E. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carci-nogenesis. J Gastroenterol Hepatol 2013;28 (Suppl 1):38-42.
142. Rollins MD, Ward RM, Jackson WD, Mulroy CW, Spencer CP, Ying J et al. Effect of decreased paren-teral soybean lipid emulsion on hepatic function in infants at risk for parenteral nutrition-associated liver disease:a pilot study. J Pediatr Surg 2013;48:1348-1356.
143. Romeiro FG, da Silva Yamashiro F, Américo MF, Corá LA, Silva GF, Miranda JR et al. Erythromycin versus neomycin in the treatment of hepatic enceph-alopathy in cirrhosis:a randomized double-blind study. BMC Gastroenterol 2013;13:13.
144. Rosberg-Cody E, Stanton C, O'Mahony L, Wall R, Shanahan F, Quigley EM et al. Recombinant lacto-bacilli expressing linoleic acid isomerase can modulate the fatty acid composition of host adipose tissue in mice. Microbiology 2011;157:609-615.
145. Ruiz L, Margolles A, Sánchez B. Bile resistance mechanisms in lactobacillus and bifidobacterium. Front Microbiol 2013;4:396.
146. Rune I, Hansen CH, Ellekilde M, Nielsen DS, Skov-gaard K, Rolin BC et al. Ampicillin-improved glucose tolerance in diet-induced obese C57BL/6NTac mice is age dependent. J Diabetes Res 2013;2013: 319321.
147. Ruiz AG, Casafont F, Crespo J, Cayón A, Mayorga M, Estebanez A et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients:evidence for the potential role of endotoxin in the pathogenesis of nonalcoholic steatohepatitis. Obes Surg 2007;17: 1374-1380.
148. Sabaté JM, Jouët P, Harnois F, Mechler C, Msika S, Grossin M et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesi-ty:a contributor to severe hepatic steatosis. Obes Surg 2008;18:371-377.
149. Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth:pathogenesis and clinical significance. Ther Adv Chronic Dis 2013;4:223-231.
150. Santacruz A, Marcos A, Wärnberg J, Martí A, Mar-tin-Matillas M, Campoy C et al. Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity (Silver Spring) 2009;17:1906-1915.
151. Sato T, Morita A, Mori N, Miura S. The role of gly-cerol-3-phosphate dehydrogenase 1 in the progression of fatty liver after acute ethanol administration in mice. Biochem Biophys Res Commun 2014; 444:525-530.
152. Savarino E, Assandri L, Giannini EG, Savarino V. Small intestinal bacterial overgrowth and Helicobac-ter pylori: can they be cause of thrombocytopenia in patients with chronic liver disease? Am J Gastro-enterol 2011;106:1171-1172.
153. Savassi-Rocha AL, Diniz MT, Vilela EG, Diniz Mde F, Sanches SR, da Cunha AS et al. Changes in intestinal permeability after roux-en-y gastric bypass. Obes Surg 2014;24:184-190.
154. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013;17:225-235.
155. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroente-rology 2014;146:1513-1524.
156. Schroeder N, Marquart LF, Gallaher DD. The role of viscosity and fermentability of dietary fibers on satiety- and adiposity-related hormones in rats. Nutrients 2013;5:2093-2113.
157. Schugar RC, Huang X, Moll AR, Brunt EM, Crawford PA. Role of choline deficiency in the fatty liver phenotype of mice fed a low protein, very low carbohydrate ketogenic diet. PLoS One 2013;8:e74806.
158. Seo YS, Shah VH. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol 2012;18:337-346.
159. Shanab AA, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F et al. Small intestinal bacterial overgrowth in non-alcoholic steatohepati-tis:association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011;56:1524-1534.
160. Shavakhi A, Minakari M, Firouzian H, Assali R, Hekmatdoost A, Ferns G. Effect of a probiotic and metformin on liver aminotransferases in nonalcoholic steatohepatitis: a double blind randomized clinical trial. Int J Prev Med 2013;4:531-537.
161. Shen J, Sakaida I, Uchida K, Terai S, Okita K. Lep-tin enhances TNF-alpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells. Life Sci 2005;77:1502-1515.
162. Soriano G, Sánchez E, Guarner C, Schiffrin EJ. Lac-tobacillus johnsonii La1 without antioxidants does not decrease bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. J Hepatol 2012; 57:1395-1396.
163. Sorini C, Falcone M. Shaping the (auto)immune response in the gut:the role of intestinal immune regulation in the prevention of type 1 diabetes. Am J Clin Exp Immunol 2013;2:156-171.
164. Sorrentino P, Tarantino G, Conca P, Perrella A, Ter-racciano ML, Vecchione et al. Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 2004;41:751-757.
165. Stanković MN, Mladenović DR, Duričić I, Sobajić SS, Timić J, Jorgačević B et al. Time-dependent changes and association among liver free fatty acids, serum lipid profile and histological features in mice model of nonalchoholic fatty liver disease. Arch Med Res 2014;45:116-124.
166. Stenkamp-Strahm CM, Kappmeyer AJ, Schmalz JT, Gericke M, Balemba O. High-fat diet ingestion correlates with neuropathy in the duodenum myenteric plexus of obese mice with symptoms of type 2 diabetes. Cell Tissue Res 2013;354:381-394.
167. Stewart RK, Dangi A, Huang C, Murase N, Kimura S, Stolz DB et al. A novel mouse model of depletion of stellate cells clarifies their role in ischemia/reper-fusion- and endotoxin-induced acute liver injury. J Hepatol 2014;60:298-305.
168. Strasser F. Clinical application of ghrelin. Curr Pharm Des 2012;18:4800-4812.
169. Sugatani J, Sadamitsu S, Wada T, Yamazaki Y, Ikari A, Miwa M. Effects of dietary inulin, statin, and their co-treatment on hyperlipidemia, hepatic steato-sis and changes in drug-metabolizing enzymes in rats fed a high-fat and high-sucrose diet. Nutr Metab (Lond) 2012;9:23.
170. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013;368:1575-1584.
171. Tannock GW. Analysis of the intestinal microflora using molecular methods. Eur J Clin Nutr 2002;56 (Suppl 4):S44-S49.
172. Tarantino G. Utility of sonography in diagnosing hepatocellular carcinoma. AJR Am J Roentgenol 2007;188:W494;author reply W495.
173. Tarantino G, Capone D. Inhibition of the mTOR pathway:a possible protective role in coronary artery disease. Ann Med 2013;45:348-356.
174. Tarantino G, Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol 2013;19: 3375-3384.
175. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease:further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007;22:293-303.
176. Tarantino G, Colicchio P, Conca P, Finelli C, Di Minno MN, Tarantino M et al. Young adult obese subjects with and without insulin resistance:what is the role of chronic inflammation and how to weigh it non-invasively? J Inflamm (Lond) 2009;6:6.
177. Tarantino G, Savastano S, Colao A. Hepatic steato-sis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Ga-stroenterol 2010;16:4773-4783.
178. Tarantino G, Colao A, Capone D, Conca P, Taranti-no M, Grimaldi E et al. Circulating levels of cyto-chrome C, gamma-glutamyl transferase, triglycer-ides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. J Biol Regul Homeost Agents 2011a;25:47-56.
179. Tarantino G, Scopacasa F, Colao A, Capone D, Ta-rantino M, Grimaldi E et al. Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease.World J Gastroenterol 2011b;17: 5280-5288.
180. Tarantino G, Finelli C, Colao A, Capone D, Taranti-no M, Grimaldi E et al. Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase? J Transl Med 2012;10:50.
181. Tarantino G, Capone D, Finelli C. Exposure to ambient air particulate matter and non-alcoholic fatty liver disease. World J Gastroenterol 2013;19:3951-3956.
182. Tarantino G, Citro V, Finelli C. Recreational drugs: a new health hazard for patients with concomitant chronic liver diseases. J Gastrointest Liver Dis 2014; 23:79-84.
183. Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki SI, Kuwahara A. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol 2008;59(Suppl 2):251-262.
184. Tilg H. Obesity, metabolic syndrome, and microbio-ta:multiple interactions. J Clin Gastroenterol 2010; 44(Suppl 1):S16-S18.
185. Tomaro-Duchesneau C, Saha S, Malhotra M, Jones ML, Labbé A, Rodes L et al. Effect of orally administered L. fermentum NCIMB 5221 on markers of metabolic syndrome:an in vivo analysis using ZDF rats. Appl Microbiol Biotechnol 2014;98:115-126.
186. Trapecar M, Goropevsek A, Gorenjak M, Gradisnik L, Slak Rupnik M. A co-culture model of the developing small intestine offers new insight in the early immunomodulation of enterocytes and macrophages by lactobacillus spp. through STAT1 and NF-kB p65 translocation. PLoS One 2014;9:e86297.
187. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010;28:220-224.
188. Tuohy KM, Fava F, Viola R. The way to a man's heart is through his gut microbiota' - dietary pro- and prebiotics for the management of cardiovascular risk. Proc Nutr Soc 2014:1-14.
189. Valdés-Ramos R, Martínez-Carrillo BE, Aranda-González II, Guadarrama AL, Pardo-Morales RV, Tlatempa P et al. Diet, exercise and gut mucosal immunity. Proc Nutr Soc 2010;69:644-650.
190. van Baarlen P, Troost FJ, van Hemert S, van der Meer C, de Vos WM, de Groot PJ et al. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci U S A 2009;106:2371-2376.
191. van der Hoeven-Hangoor E, van derVossen JM, Schuren FH, Verstegen MW, de Oliveira JE, Mon-tijn RC et al. Ileal microbiota composition of broilers fed various commercial diet compositions. Poult Sci 2013;92:2713-2723.
192. Vansaun MN, Mendonsa AM, Lee Gorden D. Hepa-tocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of no-nalchoholic fatty liver disease. PLoS One 2013;8: e73054.
193. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients 2011;3:858-876.
194. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49:306-317.
195. Wang LX, Liu K, Gao DW, Hao JK. Protective effects of two Lactobacillus plantarum strains in hy-perlipidemic mice. World J Gastroenterol 2013a; 19:3150-3156.
196. Wang Y, Liu Y, Kirpich I, Ma Z, Wang C, Zhang M et al. Lactobacillus rhamnosus GG reduces hepatic TNFα production and inflammation in chronic alcohol-induced liver injury. J Nutr Biochem 2013b;24: 1609-1615.
197. Wattacheril J, Seeley EH, Angel P, Chen H, Bowen BP, Lanciault C et al. Differential intrahepatic phos-pholipid zonation in simple steatosis and nonalcoholic steatohepatitis. PLoS One 2013;8:e57165.
198. Wen SH, Li Y, Li C, Xia ZQ, Liu WF, Zhang XY et al. Ischemic postconditioning during reperfusion attenuates intestinal injury and mucosal cell apoptosis by inhibiting JAK/STAT signaling activation. Shock 2012;38:411-419.
199. Whelan K. Mechanisms and effectiveness of prebi-otics in modifying the gastrointestinal microbiota for the management of digestive disorders. Proc Nutr Soc 2013;72:288-298.
200. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol 2014; 60:197-209.
201. Wolf G. Gut microbiota: a factor in energy regulation. Nutr Rev 2006;64:47-50.
202. Wu WC, Zhao W, Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J Gastroenterol 2008;14:313-317.
203. Ye Q, Wang X, Wang Q, Xia M, Zhu Y, Lian F et al. Cytochrome P4502E1 inhibitor, chlormethiazole, decreases lipopolysaccharide-induced inflammation in rat Kupffer cells with ethanol treatment. Hepatol Res 2013;43:1115-1123.
204. Yokota A, Fukiya S, Islam KB, Ooka T, Ogura Y, Hayashi T et al. Is bile acid a determinant of the gut microbiota on a high-fat diet? Gut Microbes 2012;3: 455-459.
205. Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L. Systematic review with meta-analysis: nonalcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014;39:3-14.
206. Zhao WX, Wang L, Yang JL, Li LZ, Xu WM, Li T. Caffeic acid phenethyl ester attenuates pro-inflammatory and fibrogenic phenotypes of LPS-stimulated hepatic stellate cells through the inhibition of NF-κB signaling. Int J Mol Med 2014;33: 687-694.
207. Zheng W, Hou Y, Su Y, Yao W. Lactulose promotes equol production and changes the microbial community during in vitro fermentation of daidzein by fecal inocula of sows. Anaerobe 2014;25:47-52.
208. Zhong J, Rao X, Deiuliis J, Braunstein Z, Narula V, Hazey J et al. A potential role for dendritic cell/ ma-crophage-expressing DPP4 in obesity-induced visceral inflammation. Diabetes 2013;62:149-157.
209. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients:a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-609.
210. Zocco MA, Ainora ME, Gasbarrini G, Gasbarrini A. Bacteroides thetaiotaomicron in the gut:molecular aspects of their interaction. Dig Liver Dis 2007;39: 707-712.
211. + T cells and the production of TNF-α in lipopolysaccharide-stimulated monocytes from obese human subjects. Br J Nutr 2013;110:2011-2019.